Please assess the completion status of the following clinical trial:

Trial Title: Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Age 4 through 55 years~* Clinical history of allergy to peanuts or peanut-containing foods~* Serum immunoglobulin E (IgE) to peanut ≥0.35 kUA/L (kilos of allergen-specific units per liter, determined by UniCAP™\* within the past 12 months) and/or a skin prick test (SPT) to peanut ≥3 mm compared to control~* Experience dose-limiting symptoms at or before the 100 mg challenge dose of peanut protein (measured as 200 mg of peanut flour) on Screening DBPCFC conducted in accordance with PRACTALL\*\* guidelines~* Not be residing at the same address as another subject in this or any peanut OIT study~UniCAP™\*: a laboratory system for routine diagnostic testing of allergy and tool for basic studies on allergens and antibodies~PRACTALL\*\*: PRACTical issues in ALLergology Joint United States/European Union Initiative~Key Exclusion Criteria:~* History of cardiovascular disease, including uncontrolled or inadequately controlled hypertension~* History of severe or life-threatening episode of anaphylaxis or anaphylactic shock within 60 days of Screening DBPCFC~* History of chronic disease (other than asthma, atopic dermatitis, or allergic rhinitis) that is, or is at significant risk of becoming, unstable or requiring a change in chronic therapeutic regimen~* History of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD), symptoms of dysphagia or recurrent gastrointestinal symptoms of undiagnosed etiology~* History of severe asthma (NHLBI criteria steps 5 or 6), or mild to moderate asthma (2007 NHLBI criteria steps 1-4) that is uncontrolled or difficult to control~* History of steroid medication use~* History of a mast cell disorder, including mastocytosis, urticarial pigmentosa, and hereditary or idiopathic angioedema~* Developing dose-limiting symptoms in reaction to the placebo part of the Screening DBPCFC~* Having the same place of residence as another subject in the study

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- AR101 powder provided in capsules & sachets (Type: EXPERIMENTAL): Study product provided as peanut protein in pull-apart capsules or sachets
- Placebo powder provided in capsules & sachets (Type: PLACEBO_COMPARATOR): Placebo formulation in pull-apart capsules or sachets containing only inactive ingredients

Based on this trial design, predict the completion outcome and termination type (if applicable).